Naturally occurring infections in non-human primates (NHP) and immunotoxicity implications: Discussion sessions
Kenneth J. Olivier(Merrimack Pharmaceuticals (United States)), Ellen W. Evans(Merck Biopharma Co., Ltd. (Japan)), Keith G. Mansfield(Novartis (United States)), Joe H. Simmons(The University of Texas MD Anderson Cancer Center), Nicholas W. Lerche(Primate Conservation), David Hutto(Animal and Plant Health Inspection Service), Karen Price(Purchase College), Yanli Ouyang(United States Food and Drug Administration), L. Peyton Myers(United States Food and Drug Administration), Katrina A. Taylor(Bristol-Myers Squibb (Germany))
Cited by 8
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations
|Vaccine|2011|310
Biogeography of the Intestinal Mucosal and Lumenal Microbiome in the Rhesus Macaque
|Cell Host & Microbe|2015|308
Pathogenic Simian Immunodeficiency Virus Infection Is Associated with Expansion of the Enteric Virome
|Cell|2012|279
A global catalog of whole-genome diversity from 233 primate species
|Science|2023|211